HIV in body fluids during primary HIV infection: implications for pathogenesis, treatment and public health.
about
Cerebrospinal fluid HIV infection and pleocytosis: relation to systemic infection and antiretroviral treatmentPrevention strategies for blood-borne viruses-in the Era of vaccines, direct acting antivirals and antiretroviral therapySpatial epidemiology of recently acquired HIV infections across rural and urban areas of North CarolinaAmplified transmission of HIV-1: missing link in the HIV pandemicClinical and Mucosal Immune Correlates of HIV-1 Semen Levels in Antiretroviral-Naive Men.HIV-1 Populations in Semen Arise through Multiple Mechanisms.The Development and Implementation of an Outreach Program to Identify Acute and Recent HIV Infections in New York City.Transmitted antiretroviral drug resistance among acute and recent HIV infections in North Carolina from 1998 to 2007Genetic variation and HIV-associated neurologic disease.Acute HIV infection among pregnant women in MalawiGenital tract sequestration of SIV following acute infectionHIV dynamics in seminal plasma during primary HIV infectionSingle genome analysis reveals genetic characteristics of Neuroadaptation across HIV-1 envelope.Finding those at risk: acute HIV infection in Newark, NJ.Post-prostatic massage fluid/urine as an alternative to semen for studying male genitourinary HIV-1 sheddingMinocycline fails to modulate cerebrospinal fluid HIV infection or immune activation in chronic untreated HIV-1 infection: results of a pilot studyA conceptual model of interventions to increase diagnosis of acute HIV infection and reduce forward transmission.Role of acute and early HIV infection in the sexual transmission of HIV.Central nervous system immune activation characterizes primary human immunodeficiency virus 1 infection even in participants with minimal cerebrospinal fluid viral burden.HIV-1 target cells in the CNS.Compartmentalized replication of R5 T cell-tropic HIV-1 in the central nervous system early in the course of infection.Raltegravir treatment intensification does not alter cerebrospinal fluid HIV-1 infection or immunoactivation in subjects on suppressive therapyAnogenital HIV RNA in Thai men who have sex with men in Bangkok during acute HIV infection and after randomization to standard vs. intensified antiretroviral regimens.Compartmentalization, Viral Evolution, and Viral Latency of HIV in the CNS.Pre-exposure prophylaxis and antiretroviral resistance: HIV prevention at a cost?Acute HIV revisited: new opportunities for treatment and prevention.Comparative study of methods for detecting sequence compartmentalization in human immunodeficiency virus type 1.Detection of acute HIV infection: a field evaluation of the determine® HIV-1/2 Ag/Ab combo testThe cerebrospinal fluid proteome in HIV infection: change associated with disease severityHIV-1-related central nervous system disease: current issues in pathogenesis, diagnosis, and treatment.Are there benefits to starting antiretroviral therapy during primary HIV infection? Conclusions from the Seattle Primary Infection Cohort vary by control groupA novel role for APOBEC3: susceptibility to sexual transmission of murine acquired immunodeficiency virus (mAIDS) is aggravated in APOBEC3 deficient mice.Maximizing the impact of HIV prevention efforts: interventions for couples.Antiretroviral treatment effect on immune activation reduces cerebrospinal fluid HIV-1 infectionInvestigating a sexual network of black men who have sex with men: implications for transmission and prevention of HIV infection in the United StatesIncorporating Acute HIV Screening into Routine HIV Testing at Sexually Transmitted Infection Clinics, and HIV Testing and Counseling Centers in Lilongwe, Malawi.Cerebrospinal fluid and neuroimaging biomarker abnormalities suggest early neurological injury in a subset of individuals during primary HIV infection.Antiretroviral therapy and central nervous system HIV type 1 infectionNovel methodology for antiretroviral quantitation in the female genital tractAmplified transmission of HIV-1: comparison of HIV-1 concentrations in semen and blood during acute and chronic infection.
P2860
Q24814874-E5934216-E6FB-45E5-B71C-98F6DEC35E5DQ28076466-702AE09E-7DC6-4F30-9A92-32BA08E76B59Q28539673-43D643F0-6547-49A0-8C27-F475CF5EC4F9Q30369759-98B68173-0398-4119-8D2B-19DF86B5E17CQ33647158-68C3B624-C213-4D4B-A073-5D00F4877420Q33680752-34F9A7F4-8857-4CCF-B680-95692908D840Q33779354-3D0EF69E-C4C9-480C-ADAF-136EC40085DEQ33814896-04A42478-E06D-465E-BE61-AF1C7B6F9B9CQ33819189-3D66F25C-FE4C-414D-BCC1-CB0822C6808AQ33829950-78F6D8CF-B8AF-4D23-BFCF-53F1FBB7D80DQ33838382-4CAC6C5A-B4BA-4252-83F7-FD5CB209E351Q34083267-B52F0328-A7B1-4055-BFE2-9E305C3CBC3CQ34091371-2943AFCC-8127-45D5-A9CB-BD3E9EAB683FQ34701577-E70933A4-6DF8-4348-8D38-33CA0DF207B0Q34786803-23015ACE-EEEC-419D-A01D-CF44BCBAD061Q35052651-84DD42B9-0AF1-45B8-95BD-2B5054A0242EQ35061881-B2A24796-0A2B-456A-96D5-B7BEFED82ED1Q35087462-8A16ED27-8B17-41B1-943F-E9B1D22BD1B2Q35164448-86CAE48D-F903-4E72-B8D4-77CE8D08670BQ35196509-9A505867-74BF-47DC-B0CC-633D9A15285DQ35219829-D8BC8503-0BB2-40AB-BEDC-374B9AE7B6B4Q35532868-4E0FDB07-F70B-4AE9-B5AB-093C8867DBF8Q35588077-39792243-8C5D-4790-B4B8-AA36748B50A9Q35606068-758DC00E-3D7B-4FA1-BE3B-9746A18D9167Q35636514-E47F5225-41DB-4065-BA3E-5A9E8FDCB38AQ35730339-FB9410E7-60EE-415B-ACA9-72EBFD221534Q35857191-09583540-7BD5-4E1C-9DFB-881403D7272DQ35868122-66237FE2-74AE-4D3F-9897-84FA52717A7FQ35965332-96DD27B0-5B32-4041-A025-33C18C614416Q36009246-92F16194-DB5B-40AD-9C81-E072E0E64B94Q36136406-B9FCDE05-9659-4412-9A0F-B80DA182144DQ36161438-7FE01CC3-2B54-48FC-AF05-C991E8F97F1BQ36331519-16AA1BBC-C617-4E8B-839A-C39FD7FEE7AEQ36344916-22185C96-8943-4B94-A4CE-F9CDEB69E3E0Q36388908-4C798009-FBAA-40E5-A9B8-9574F72ECBC4Q36576458-F5D8AC12-51C9-49D9-BAAC-FF5A505826C0Q36796560-AFE2FAF0-E31C-468D-91CC-E0B37AA862E4Q37066982-DB8EF420-30C5-46F8-9F10-590A6152C1B5Q37158604-74AAB61B-5C6C-49F2-8644-5ED8DA0A4457Q37170172-05B2D6A3-E8F6-4215-BD68-4DAB4FA99E0F
P2860
HIV in body fluids during primary HIV infection: implications for pathogenesis, treatment and public health.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
HIV in body fluids during prim ...... , treatment and public health.
@en
HIV in body fluids during prim ...... , treatment and public health.
@nl
type
label
HIV in body fluids during prim ...... , treatment and public health.
@en
HIV in body fluids during prim ...... , treatment and public health.
@nl
prefLabel
HIV in body fluids during prim ...... , treatment and public health.
@en
HIV in body fluids during prim ...... , treatment and public health.
@nl
P2093
P1433
P1476
HIV in body fluids during prim ...... , treatment and public health.
@en
P2093
Eron JJ Jr
Pilcher CD
P304
P356
10.1097/00002030-200105040-00004
P407
P577
2001-05-01T00:00:00Z